Somatotropin - Biosimilar Insight, 2022
This report can be delivered to the clients within 48-72 hours
DelveInsight’s, “Somatropin– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Somatropin Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Somatropin: Overview
Somatropin is used to treat growth failure in children and adults who lack natural growth hormone. This includes people with short stature due to Noonan syndrome, Turner syndrome, Prader-Willi syndrome, short stature at birth with no catch-up growth, and other causes. hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
Somatropin Biosimilars: Drugs Chapters
This segment of the Somatropin report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Somatropin Biosimilars: Marketed Drugs
Further product details are provided in the report……..
Somatropin Biosimilars: Emerging Drugs
Further product details are provided in the report……..
Somatropin: Therapeutic Assessment
This segment of the report provides insights about the different Somatropin biosimilars segregated based on following parameters that define the scope of the report, such as:
Somatropin: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Somatropin biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Somatropin biosimilar drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Somatropin– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Somatropin Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Somatropin: Overview
Somatropin is used to treat growth failure in children and adults who lack natural growth hormone. This includes people with short stature due to Noonan syndrome, Turner syndrome, Prader-Willi syndrome, short stature at birth with no catch-up growth, and other causes. hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
Somatropin Biosimilars: Drugs Chapters
This segment of the Somatropin report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Somatropin Biosimilars: Marketed Drugs
- Omnitrope: Sandoz
Further product details are provided in the report……..
Somatropin Biosimilars: Emerging Drugs
- Somatropin beta-1b biosimilar: Harvest Moon Pharmaceuticals
Further product details are provided in the report……..
Somatropin: Therapeutic Assessment
This segment of the report provides insights about the different Somatropin biosimilars segregated based on following parameters that define the scope of the report, such as:
- Major Players in Somatropin
- Phases
- Marketed stage products
- Late stage products (BLA Filed and Phase III)
- Mid-stage products (Phase II and
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intramuscular
- Molecule Type
- Monoclonal antibodies
- Peptide
- Protein
- Small molecule
- Product Type
Somatropin: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Somatropin biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Somatropin biosimilar drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Somatropin R&D. The therapies under development are focused on novel approaches to treat/improve Somatropin.
- Somatropin Biosimilar Pipeline Analysis
- Therapeutic Assessment
- Sales Assessment
- Unmet Needs
- Impact of Drugs
- Marketed Product profiles
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Sales Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Somatropin Biosimilars?
- How many Somatropin biosimilars are developed by each company?
- How many emerging biosimilars are in mid-stage, and late-stage?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Somatropin biosimilars therapeutics?
- What are the clinical studies going on for Somatropin biosimilars and their status?
- What are the key designations that have been granted to the emerging drugs?
- USV
- Sedico
- Sandoz
- rEVO Biologics
- Reliance Life Sciences
- Polus BioPharm
- Pfizer
- Inbiopro Solutions
- Harvest Moon Pharmaceuticals
- Cristalia
- CinnaGen
- Biosidus
- BioPartners
- Bio-Ker
- AryaTinaGene
- Amega Biotech
- Human growth hormone biosimilar
- Somatropin (rDNA origin)
- Omnitrope
- Human growth hormone
- R-TPR-007
- SomatoRel
- PDP805
- Genotonorm
- IBPB 003HH
- Somatotropin biosimilar
- r-hGH Cristalia
- Cinnatropin
- Growmax
- Valtropin
- Recombinant somatropin
- Somatropin biosimilar
- Recombinant human growth hormone
1. KEY INSIGHTS
2. SOMATROPIN BIOSIMILARS: SNAPSHOT
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. REGULATORY OUTLOOK FOR BIOSIMILARS
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. SOMATROPIN (REFERENCE PRODUCT: GENOTROPIN)
5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones
6. RESEARCH AND DEVELOPMENT
6.1. Clinical Trials Information
6.2. Safety and Efficacy
7. GENOTROPIN BIOSIMILAR: EMERGING OPPORTUNITIES
*More variants of Somatropin would be added in the final report
8. SOMATROPIN: BIOSIMILARS ASSESSMENT
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. SOMATROPIN BIOSIMILARS PROFILES: BY COMPANY
9.1.1. Sandoz
9.1.1.1. Omnitrope: Sandoz
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Pfizer
9.1.2.1. Genotonorm: Pfizer
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
*More Companies and products would be added in the final report
10. SOMATROPIN BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY
11. SOMATROPIN BIOSIMILARS: COMPETITIVE LANDSCAPE
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report
12. MARKET DRIVERS
13. MARKET BARRIERS
14. SWOT ANALYSIS
15. APPENDIX
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research
16. BIBLIOGRAPHY
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
2. SOMATROPIN BIOSIMILARS: SNAPSHOT
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. REGULATORY OUTLOOK FOR BIOSIMILARS
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. SOMATROPIN (REFERENCE PRODUCT: GENOTROPIN)
5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones
6. RESEARCH AND DEVELOPMENT
6.1. Clinical Trials Information
6.2. Safety and Efficacy
7. GENOTROPIN BIOSIMILAR: EMERGING OPPORTUNITIES
*More variants of Somatropin would be added in the final report
8. SOMATROPIN: BIOSIMILARS ASSESSMENT
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. SOMATROPIN BIOSIMILARS PROFILES: BY COMPANY
9.1.1. Sandoz
9.1.1.1. Omnitrope: Sandoz
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Pfizer
9.1.2.1. Genotonorm: Pfizer
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
*More Companies and products would be added in the final report
10. SOMATROPIN BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY
11. SOMATROPIN BIOSIMILARS: COMPETITIVE LANDSCAPE
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report
12. MARKET DRIVERS
13. MARKET BARRIERS
14. SWOT ANALYSIS
15. APPENDIX
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research
16. BIBLIOGRAPHY
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
